Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Acute Effects of Rhodiola Rosea and Caffeine on Mean Propulsive Velocity Loss in Resistance Training (Rhocaf2)

4 de noviembre de 2026 actualizado por: MARINA MEDINA CORRALES

The Acute Effects of 1,000 mg of Rhodiola Rosea and 3 mg/kg of Caffeine on Mean Propulsive Velocity Loss in Advanced Resistance-Trained Subjects: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial

The goal of this clinical trial is to evaluate if combined acute supplementation with Rhodiola rosea and caffeine is superior to single-ingredient intake or placebo in attenuating neuromuscular fatigue in advanced resistance-trained subjects.

The main questions it aims to answer are:

Does combined supplementation attenuate mean propulsive velocity loss during heavy resistance exercise? Does combined supplementation reduce ratings of perceived exertion and increase repetitions performed to failure?

Researchers will compare four experimental conditions (placebo, caffeine alone, Rhodiola rosea alone, and combined supplementation) in a randomized crossover design to see if co-ingestion provides superior anti-fatigue benefits.

Participants will:

Complete a familiarization session to establish individual strength baselines. Attend 4 testing visits separated by a 72-hour washout period. Ingest the assigned treatment before testing. Perform a back squat fatigue protocol (3 sets at 70% 1RM) and complete perceptual evaluations.The goal of this clinical trial is to evaluate if combined acute supplementation with Rhodiola rosea and caffeine is superior to single-ingredient intake or placebo in attenuating neuromuscular fatigue in advanced resistance-trained subjects.

The main questions it aims to answer are:

Does combined supplementation attenuate mean propulsive velocity loss during heavy resistance exercise? Does combined supplementation reduce ratings of perceived exertion and increase repetitions performed to failure?

Researchers will compare four experimental conditions (placebo, caffeine alone, Rhodiola rosea alone, and combined supplementation) in a randomized crossover design to see if co-ingestion provides superior anti-fatigue benefits.

Participants will:

Complete a familiarization session to establish individual strength baselines. Attend 4 testing visits separated by a 72-hour washout period. Ingest the assigned treatment before testing. Perform a back squat fatigue protocol (3 sets at 70% 1RM) and complete perceptual evaluations.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This study is a randomized, double-blind, placebo-controlled, four-arm crossover trial designed to investigate the acute neuromuscular and ergogenic effects of single and combined supplementation with Rhodiola rosea (1,000 mg) and caffeine (3 mg/kg) in advanced resistance-trained subjects.

Neuromuscular fatigue during heavy resistance training impairs movement velocity, power output, and overall volume performance. While caffeine is a central nervous system stimulant that enhances motor unit recruitment and reduces perceived exertion, Rhodiola rosea is an adaptogen proposed to modulate central monoamines and attenuate fatigue during high-intensity effort. This protocol evaluates whether co-ingestion provides a synergistic advantage over isolated administration or placebo in maintaining movement execution quality and accelerating acute recovery.

Study Procedures:

Familiarization Session: Prior to the experimental trials, participants complete a familiarization session to establish baseline measurements and estimate 1-repetition maximum (1RM) in the barbell back squat using a two-point load-velocity method (using loads corresponding to ~1.0 m/s and ~0.5 m/s) with a linear position transducer.

Experimental Trials (4 Visits): Participants complete four experimental testing visits in a randomized, counterbalanced order, separated by a 72-hour washout period.

During each of the 4 experimental visits, participants complete the following sequence:

Supplement Ingestion: Double-blind administration of the assigned treatment:

Rhodiola placebo consists of opaque cornstarch capsules. Caffeine placebo consists of a 60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid.

Active conditions consist of 1,000 mg of Rhodiola rosea and/or 3 mg/kg of caffeine.

Pre-Exercise Evaluation: Completion of baseline perceptual questionnaires. Velocity Determination: Identification of the exact load corresponding to a Mean Propulsive Velocity (MPV) of 1.0 ± 0.03 m/s in the back squat.

Acute Fatigue Protocol: Execution of 3 sets at 70% estimated 1RM in the back squat performed to muscular failure, recording total repetitions and velocity loss across sets.

Post-Fatigue Velocity Recovery: Re-assessment of MPV using the pre-determined 1.0 m/s load at exactly 1 minute and 2 minutes post-fatigue protocol to evaluate acute neuromuscular fatigue and velocity recovery.

Perceptual Evaluation: Rating of Perceived Exertion (RPE) recorded post-exercise.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

20

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: David Gomez Castillo, PhD Candidate
  • Número de teléfono: +52 2382091643
  • Correo electrónico: david.gomezcs@uanl.edu.mx

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Nuevo León
      • San Nicolás, Nuevo León, México, 66455
        • Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 35 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Healthy males and females.
  • Advanced resistance training experience (as defined by Santos et al., 2021): 1 to 3 years of consistent resistance training experience, demonstrating proper barbell back squat technique.
  • Relative maximum strength (estimated 1RM back squat): Minimum of 150% of body mass for men, and 130% of body mass for women.
  • Habitual caffeine consumers (e.g., daily intake via coffee, tea, sports gels, or energy drinks).
  • Commitment to maintaining current nutritional habits and training routines throughout the study period.
  • Ensured stable consumption of dietary supplements with cumulative effects (e.g., creatine, beta-alanine, nitrates, citrulline, betaine) for at least one month prior to and throughout the experimental protocol, with a commitment to not alter the dosage. Intake will be recorded and standardized.
  • Availability to attend all scheduled evaluations.
  • Provision of written informed consent validating full understanding of the study protocols.

Exclusion Criteria:

  • Presence of cardiovascular diseases (e.g., arterial hypertension, arrhythmias) or metabolic disorders (e.g., type 1 or type 2 diabetes mellitus).
  • At least one affirmative response on the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+).
  • History of anabolic steroid use (less than 4 years) or use of World Anti-Doping Agency (WADA) prohibited performance-enhancing substances.
  • Consumption of supplements with acute ergogenic effects (e.g., coffee, energy drinks, pre-workout supplements) within 12 hours prior to testing sessions, or failure to comply with a minimum 4-hour fasting period prior to the experimental session. (Note: Subjects violating these criteria will have their session rescheduled).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación cruzada
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo

Placebo condition consisting of opaque cornstarch capsules and a 60 mL placebo liquid solution.

Opaque cornstarch capsules matching the active Rhodiola capsules.

60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid.

Experimental: Caffeine

Single administration of caffeine alongside placebo capsules.

Opaque cornstarch capsules matching the active Rhodiola capsules.

3 mg/kg of caffeine administered in a 60 mL liquid solution.

Experimental: Rhodiola rosea

Single administration of Rhodiola rosea alongside placebo liquid solution.

60 mL liquid solution containing sweetener, 3 g of sugar, and 1 g of citric acid.

1,000 mg of Rhodiola rosea administered in opaque capsules.

Experimental: Rhodiola rosea + Caffeine

Combined administration of Rhodiola rosea and caffeine.

3 mg/kg of caffeine administered in a 60 mL liquid solution.

1,000 mg of Rhodiola rosea administered in opaque capsules.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage Loss in Mean Propulsive Velocity (MPV)
Periodo de tiempo: Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks.

Percentage loss in mean propulsive velocity (MPV) following the fatiguing protocol. MPV is assessed during the barbell back squat using an individualized load corresponding to an initial velocity of 1.0 ± 0.03 m/s, recorded via a linear position transducer. Percentage loss is calculated relative to pre-fatigue baseline as: [(baseline MPV - post-fatigue MPV) / baseline MPV] × 100. The fatiguing protocol consists of 3 sets to failure at 70% 1RM.

Baseline (pre-fatigue), 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Total Number of Repetitions to Failure
Periodo de tiempo: Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks

Cumulative number of successful repetitions completed across 3 sets at 70% 1RM performed to momentary muscular failure during the fatiguing protocol. Data are reported as the total number of repetitions completed per experimental condition.

Immediately upon completion of the fatiguing exercise protocol, up to 2 weeks
Rating of Perceived Exertion (RPE)
Periodo de tiempo: Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks

Subjective perception of effort assessed using a standardized RPE scale immediately following the fatiguing protocol to quantify internal load.

Immediately, 1 minute, and 2 minutes post-fatiguing exercise protocol, up to 2 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: José Raúl Hoyos Flores, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
  • Director de estudio: Marina Medina Corrales, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon
  • Silla de estudio: Myriam Zaraí García Dávila, PhD, Faculty of Sports Organization, Universidad Autonoma de Nuevo Leon

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

12 de octubre de 2026

Finalización primaria (Estimado)

6 de noviembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

26 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Publicado por primera vez (Actual)

9 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

4 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CEIFOD 0125028

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Marco de tiempo para compartir IPD

Data will become available after publication of the main manuscript in a peer-reviewed journal and will remain accessible indefinitely.

Criterios de acceso compartido de IPD

Data and supporting materials will be publicly accessible via the Open Science Framework (OSF) repository to any researcher interested in secondary or meta-analysis.

Tipo de información de apoyo para compartir IPD

  • CIF
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .